TriangleNCT00436618 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- years
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 5 years
What was measured
The overall survival or survival time is defined as the time from registration to death due to any cause. The distribution of overall survival was estimated using the method of Kaplan-Meier.
Analysis population: 276 out of 277 were analyzed for response. One patient was excluded because of patient refusal before starting treatment.
Groups in this outcome
Relapsed Aggressive Non-Hodgkin Lymphoma
Study 1. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time. Everolimus : Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
Relapsed Indolent Non-Hodgkin Lymphoma
Study 2. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time. Everolimus : Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
Uncommon Lymphomas
Study 3. Includes Hodgkin's lymphomas. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time. Everolimus : Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
| Group | Source count |
|---|---|
| Relapsed Aggressive Non-Hodgkin Lymphoma | 114 |
| Relapsed Indolent Non-Hodgkin Lymphoma | 55 |
| Uncommon Lymphomas | 107 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Relapsed Aggressive Non-Hodgkin Lymphoma | 0.66 | Not reported | 0.44 | 0.99 | Not reported |
| Relapsed Indolent Non-Hodgkin Lymphoma | 2.45 | Not reported | 1.04 | 4.97 | Not reported |
| Uncommon Lymphomas | 3.41 | Not reported | 2.31 | 5.13 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.44
- upper Limit
- 0.99
- value
- 0.66
- group Id
- OG001
- lower Limit
- 1.04
- upper Limit
- 4.97
- value
- 2.45
- group Id
- OG002
- lower Limit
- 2.31
- upper Limit
- 5.13
- value
- 3.41
- denoms
- counts
- group Id
- OG000
- value
- 114
- group Id
- OG001
- value
- 55
- group Id
- OG002
- value
- 107
- units
- Participants
- description
- The overall survival or survival time is defined as the time from registration to death due to any cause. The distribution of overall survival was estimated using the method of Kaplan-Meier.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Study 1. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time. Everolimus : Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
- id
- OG000
- title
- Relapsed Aggressive Non-Hodgkin Lymphoma
- description
- Study 2. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time. Everolimus : Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
- id
- OG001
- title
- Relapsed Indolent Non-Hodgkin Lymphoma
- description
- Study 3. Includes Hodgkin's lymphomas. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time. Everolimus : Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
- id
- OG002
- title
- Uncommon Lymphomas
- param Type
- MEDIAN
- population Description
- 276 out of 277 were analyzed for response. One patient was excluded because of patient refusal before starting treatment.
- reporting Status
- POSTED
- time Frame
- 5 years
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- years
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice